Ravulizumab Outcomes in Polish patients with aHUS - aHUS-OPTIMUM

Inclusion Criteria

• Inclusion Criteria:
• - Patients of all ages diagnosed with atypical hemolytic uremic syndrome (aHUS) who received treatment with ravulizumab under the National Drug Program (NDP) in Poland.
• - Patients who are willing to participate in the study and have provided informed consent by signing the informed consent form (ICF).
• Exclusion Criteria:
• - Individuals who intend to participate in a clinical trial for atypical hemolytic uremic syndrome (aHUS) on or after the date of their first ravulizumab infusion through the National Drug Program.
• - Patients with cognitive impairments, those who are unwilling to participate, or those facing language barriers that hinder adequate comprehension or cooperation.